Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1992 1
1993 1
1998 1
2000 1
2001 1
2004 1
2005 1
2006 1
2007 2
2008 2
2009 1
2012 2
2013 2
2014 1
2015 3
2016 1
2017 5
2018 4
2019 3
2020 2
2021 4
2022 7
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Results by year

Filters applied: . Clear all
Page 1
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW Jr, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC; C4591001 Clinical Trial Group. Polack FP, et al. N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10. N Engl J Med. 2020. PMID: 33301246 Free PMC article. Clinical Trial.
Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. ...
Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safet …
Self-expanding Transcatheter vs Surgical Aortic Valve Replacement in Intermediate-Risk Patients: 5-Year Outcomes of the SURTAVI Randomized Clinical Trial.
Van Mieghem NM, Deeb GM, Søndergaard L, Grube E, Windecker S, Gada H, Mumtaz M, Olsen PS, Heiser JC, Merhi W, Kleiman NS, Chetcuti SJ, Gleason TG, Lee JS, Cheng W, Makkar RR, Crestanello J, George B, George I, Kodali S, Yakubov SJ, Serruys PW, Lange R, Piazza N, Williams MR, Oh JK, Adams DH, Li S, Reardon MJ; SURTAVI Trial Investigators. Van Mieghem NM, et al. JAMA Cardiol. 2022 Oct 1;7(10):1000-1008. doi: 10.1001/jamacardio.2022.2695. JAMA Cardiol. 2022. PMID: 36001335 Free PMC article. Clinical Trial.
IMPORTANCE: In patients with severe aortic valve stenosis at intermediate surgical risk, transcatheter aortic valve replacement (TAVR) with a self-expanding supra-annular valve was noninferior to surgery for all-cause mortality or disabling stroke at 2 years. Comparisons of longe …
IMPORTANCE: In patients with severe aortic valve stenosis at intermediate surgical risk, transcatheter aortic valve replacement (TAVR) with …
A multi-country analysis of COVID-19 hospitalizations by vaccination status.
Gonçalves BP, Jassat W, Baruch J, Hashmi M, Rojek A, Dasgupta A, Martin-Loeches I, Reyes LF, Piubelli C, Citarella BW, Kartsonaki C, Lefèvre B, López Revilla JW, Lunn M, Harrison EM, Kraemer MUG, Shrapnel S, Horby P, Bisoffi Z, Olliaro PL, Merson L; ISARIC Clinical Characterisation Group. Gonçalves BP, et al. Med. 2023 Nov 10;4(11):797-812.e2. doi: 10.1016/j.medj.2023.08.005. Epub 2023 Sep 21. Med. 2023. PMID: 37738979 Free PMC article.
CONCLUSIONS: These findings will inform allocation of healthcare resources in future surges as well as design of longer-term international studies to characterize changes in clinical profile of hospitalized COVID-19 patients related to vaccination history. ...
CONCLUSIONS: These findings will inform allocation of healthcare resources in future surges as well as design of longer-term internat …
A highly potent human neutralizing antibody prevents vertical transmission of Rift Valley fever virus in a rat model.
McMillen CM, Chapman NS, Hoehl RM, Skvarca LB, Schwarz MM, Handal LS, Crowe JE Jr, Hartman AL. McMillen CM, et al. Among authors: hartman al. Nat Commun. 2023 Jul 26;14(1):4507. doi: 10.1038/s41467-023-40187-z. Nat Commun. 2023. PMID: 37495594 Free PMC article.
Women are also at risk of vertical virus transmission and late-term miscarriages. MAb RVFV-268 is a highly potent recombinant neutralizing human monoclonal antibody that targets RVFV. ...
Women are also at risk of vertical virus transmission and late-term miscarriages. MAb RVFV-268 is a highly potent recombinant neutral …
A systematic review of the role of intrapartum hypoxia-ischemia in the causation of neonatal encephalopathy.
Graham EM, Ruis KA, Hartman AL, Northington FJ, Fox HE. Graham EM, et al. Among authors: hartman al. Am J Obstet Gynecol. 2008 Dec;199(6):587-95. doi: 10.1016/j.ajog.2008.06.094. Am J Obstet Gynecol. 2008. PMID: 19084096 Review.

For nonanomalous term infants, the incidence of an umbilical arterial pH < 7.0 at birth is 3.7 of 1000, of which 51 of 297 (17.2%) survived with neonatal neurologic morbidity, 45 of 276 (16.3%) had seizures, and 24 of 407 (5.9%) died during the neonatal period. .

…

For nonanomalous term infants, the incidence of an umbilical arterial pH < 7.0 at birth is 3.7 of 1000, of which 51 of 297

…
How do you improve compliance?
Winnick S, Lucas DO, Hartman AL, Toll D. Winnick S, et al. Among authors: hartman al. Pediatrics. 2005 Jun;115(6):e718-24. doi: 10.1542/peds.2004-1133. Pediatrics. 2005. PMID: 15930200 Review.
At least one third of all patients fail to complete relatively short-term treatment regimens. Poor compliance places children at risk for problems such as continued disease, complicates the physician-patient relationship, and prevents accurate assessment of the quality of …
At least one third of all patients fail to complete relatively short-term treatment regimens. Poor compliance places children at risk …
SARS-CoV-2 control on a large urban college campus without mass testing.
O'Donnell C, Brownlee K, Martin E, Suyama J, Albert S, Anderson S, Bhatte S, Bonner K, Burton C, Corn M, Eng H, Flage B, Frerotte J, Balasubramani GK, Haggerty C, Haight J, Harrison LH, Hartman A, Hitter T, King WC, Ledger K, Marsh JW, McDonald MC, Miga B, Moses K, Newman A, Ringler M, Roberts M, Sax T, Shekhar A, Sterne M, Tenney T, Vanek M, Wells A, Wenzel S, Williams J. O'Donnell C, et al. Among authors: hartman a. J Am Coll Health. 2023 Jan 3:1-9. doi: 10.1080/07448481.2022.2153600. Online ahead of print. J Am Coll Health. 2023. PMID: 36595575
RESULTS: Random surveillance testing demonstrated a prevalence among asymptomatic students of 0.4% throughout the term. There were two surges in cases that were contained by enhanced mitigation and communication combined with targeted testing. Cumulative cases totaled 445 …
RESULTS: Random surveillance testing demonstrated a prevalence among asymptomatic students of 0.4% throughout the term. There were tw …
Association between Term Equivalent Brain Magnetic Resonance Imaging and 2-Year Outcomes in Extremely Preterm Infants: A Report from the Preterm Erythropoietin Neuroprotection Trial Cohort.
Mayock DE, Gogcu S, Puia-Dumitrescu M, Shaw DWW, Wright JN, Comstock BA, Heagerty PJ, Juul SE; Preterm Erythropoietin Neuroprotection (PENUT) Trial Consortium. Mayock DE, et al. J Pediatr. 2021 Dec;239:117-125.e6. doi: 10.1016/j.jpeds.2021.08.040. Epub 2021 Aug 26. J Pediatr. 2021. PMID: 34454953 Free PMC article. Clinical Trial.
Increased global brain abnormality and white matter injury scores at term equivalent were associated with reductions in cognitive, motor, and language abilities at 2 years of corrected age. CONCLUSIONS: Evidence of brain injury on brain MRIs obtained at term equival …
Increased global brain abnormality and white matter injury scores at term equivalent were associated with reductions in cognitive, mo …
The Impact of Erythropoietin on Short- and Long-Term Kidney-Related Outcomes in Neonates of Extremely Low Gestational Age. Results of a Multicenter, Double-Blind, Placebo-Controlled Randomized Clinical Trial.
Askenazi DJ, Heagerty PJ, Schmicker RH, Brophy P, Juul SE, Goldstein SL, Hingorani S; PENUT Trial Consortium. Askenazi DJ, et al. J Pediatr. 2021 May;232:65-72.e7. doi: 10.1016/j.jpeds.2021.01.031. Epub 2021 Jan 20. J Pediatr. 2021. PMID: 33484699 Free PMC article. Clinical Trial.
CONCLUSIONS: ELGANs have high rates of in-hospital AKI and kidney-related problems at 22-26 months of cGA. Recombinant erythropoietin may protect ELGANs against long-term elevated SBP but does not appear to protect from AKI, low eGFR, albuminuria, or elevated DBP at 22-26 …
CONCLUSIONS: ELGANs have high rates of in-hospital AKI and kidney-related problems at 22-26 months of cGA. Recombinant erythropoietin may pr …
50 results